Innovation combined drug Galvus Met (vildagliptin + metformin) in the therapy of type 2 diabetes mellitus.
We consider the current opportunities in the treatment of type 2 diabetes mellitus (type 2 diabetes), criteria for choice the optimal drug for combination therapy of this disease (in addition to metformin). These drugs include dipeptidylpeptidase-4 inhibitor vildagliptin (Galvus) which improves glycemic control in patients with type 2 diabetes by increasing the secretory response ?- and ?-cells of the pancreas and increasing their sensitivity to glucose. The results of clinical studies showed that in patients with type 2 diabetes who have not reached target values of blood glucose levels on a background of monotherapy with metformin, the use of fixed combination of vildagliptin + metformin (Galvlus Met) allow to achieve better performance of carbohydrate metabolism without increasing body weight and with minimal risk of hypoglycemia. It is noted that the use of vildagliptin both in monotherapy and in combination with metformin leads to decrease of risk of cardiovascular disease development, lipid profile improvement and decrease of blood pressure in patients with type 2 diabetes and arterial hypertension.

Keywords: Galvus Met, vildagliptin, dipeptidylpeptidase-4 inhibitors, type 2 diabetes mellitus, metformin